SYSTEMATIC REVIEW-META-ANALYSIS
Infectious Disease

Viral and atypical respiratory co-infections in COVID-19: a systematic review and meta-analysis

Bennett Davis MD1  |  Ava N. Rothrock2  |  Sarah Swetland2  |  Halle Andris2  |  Phil Davis MD2  |  Steven G. Rothrock MD2,3

1 University of Queensland, Ochsner Clinical School, Brisbane, Australia and New Orleans, New Orleans, Louisiana, USA
2 Dr. P. Phillips Hospital, Orlando Health, Orlando, Florida, USA
3 Florida State University College of Medicine, Tallahassee, Florida, USA

Abstract

Objectives: Respiratory co-infections have the potential to affect the diagnosis and treatment of COVID-19 patients. This meta-analysis was performed to analyze the prevalence of respiratory pathogens (viruses and atypical bacteria) in COVID-19 patients.

Methods: This review was consistent with Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA). Searched databases included: PubMed, EMBASE, Web of Science, Google Scholar, and grey literature. Studies with a series of SARS-CoV-2-positive patients with additional respiratory pathogen testing were included. Independently, 2 authors extracted data and assessed quality of evidence across all studies using Cochrane’s Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and within each study using the Newcastle Ottawa scale. Data extraction and quality assessment disagreements were settled by a third author. Pooled prevalence of co-infections was calculated using a random-effects model with univariate meta-regression performed to assess the effect of study subsets on heterogeneity. Publication bias was evaluated using funnel plot inspection, Begg’s correlation, and Egger’s test.

Results: Eighteen retrospective cohorts and 1 prospective study were included. Pooling of data (1880 subjects) showed an 11.6% (95% confidence interval [CI] = 6.9–17.4, I² = 0.92) pooled prevalence of respiratory co-pathogens. Studies with 100% co-pathogen testing (1210 subjects) found a pooled prevalence of 16.8% (95% CI = 8.1–27.9, I² = 0.95) and studies using serum antibody tests (488 subjects) found a pooled prevalence of 26.8% (95%, CI = 7.9–51.9, I² = 0.97). Meta-regression found no moderators affecting heterogeneity.
Conclusion: Co-infection with respiratory pathogens is a common and potentially important occurrence in patients with COVID-19. Knowledge of the prevalence and type of co-infections may have diagnostic and management implications.

KEYWORDS
COVID-19, influenza, human, mycoplasma, pneumonia, viral, respiratory tract infections

1 | BACKGROUND

A novel coronavirus, now called SARS-CoV-2, was identified as the cause of pneumonia in a cluster of patients in Wuhan, China in December of 2019. Since this initial outbreak, the identified virus has spread across the globe with the World Health Organization (WHO) declaring a global pandemic on March 11, 2020. As of May 3, 2020, there were over 3.3 million cases and 238,000 deaths reported worldwide. Initially, experts including the Centers for Disease Control (CDC) and several state health departments recommended testing individuals with fever and lower respiratory tract infections for other viruses with instructions not to test for SARS-CoV-2 if alternate infections (eg, influenza) were present. Early guidance from the WHO also recommended that clinicians only test for SARS-CoV-2 (formerly 2019-nCoV) once influenza had been ruled out. Subsequent case reports indicate that co-infections may be an important reason for delayed diagnosis of COVID-19. More recently, experts have recommended that individuals who undergo testing for SARS-CoV-2 should additionally be tested for other common respiratory pathogens besides influenza.

2 | IMPORTANCE

Information about the type and rate of respiratory co-infections has potential diagnostic and treatment implications in COVID-19. Multiple studies have described typical presenting features for those with COVID-19 with markers that aid in predicting outcome. It is unknown if co-infections alter the presentation, clinical course, or diagnostic markers (eg, laboratory or CT scan findings) used to assess progression in COVID-19. It is also possible that treatment of influenza with anti-virals and atypical bacteria with antibiotics might improve the outcome of patients co-infected with COVID-19. Alternately, individuals with co-infections may not respond to treatment in a manner similar to those without COVID-19. For these reasons, knowledge of the prevalence and type of respiratory co-infections has important management and outcome implications in COVID-19 patients.

3 | GOALS OF THIS INVESTIGATION

The purpose of this meta-analysis was to determine the prevalence and type of common respiratory co-infections including infections due to respiratory viruses and atypical bacteria in individuals who are SARS-CoV-2-positive.

4 | METHODS

This protocol was consistent with the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) methodology (Supporting Information Table S1). The protocol was registered with the Center for Open Science’s Open Science Framework: citation osf.io/x4q3z. Our study was performed to analyze the prevalence of respiratory virus and atypical bacteria (eg, Chlamydia, Legionella, and Mycoplasma) co-infections in patients infected with SARS-CoV-2.

4.1 | Data sources and search

We performed a comprehensive literature search of the National Library of Medicine’s PubMed, EMBASE, Web of Science (version 5.34) and Google Scholar (top 1000 results for Google Scholar). A targeted grey literature search was performed using OpenGrey, Clinical Trials.gov, and the Clinical Trials Registry Platform/ICTRP (Supporting Information Table S2). Preliminary searches were initially performed on March 30 and 31, with repeated daily searches until April 11, 2020.

The database search strategy was developed by 2 study authors (SGR and PD) and adapted from published meta-analyses that evaluated respiratory co-infections. When available, we used controlled indexing language or controlled vocabularies to conduct searches with databases. The following medical subject headings (MeSH) were used when searching PubMed: COVID-19, severe acute respiratory syndrome coronavirus 2, adenoviridae infection, alphacoronavirus, betacoronavirus, bocavirus, Bordetella pertussis, Chlamydothilia pneumoniae, cytomegalovirus, enterovirus, influenza, legionella, metapneumovirus, Mycoplasma pneumoniae, parainfluenza, respiratory syncytial virus, and rhinovirus. Non-MeSH terms added to the PubMed search included: 2019-nCoV, adenovirus, and Chlamydia pneumoniae. Emtree subject headings were used when searching EMBASE: adenoviridae, alphacoronavirus, betacoronavirus, bocavirus infection, bordetella, Chlamydia OR Chlamydiae, COVID-19 (candidate term), cytomegalovirus, enterovirus, human parainfluenza virus 1, human parainfluenza virus 2, human parainfluenza virus 3, human parainfluenza virus 4, metapneumovirus, Legionella, Mycoplasma, pertussis, pneumovirus, respiratory syncytial virus infection, and rhi-
novirus. The Web of Science search was limited to the Science Citation Index, Conference Proceedings Citation Index-Science and Social Sciences/Humanities, and the Emerging Sources Citation Index. Search limits included human studies and study dates (2019 to 2020) for all databases. No study design, language or age restrictions were included in any database searches (Supporting Information Table S2). Selected titles and abstracts from each search were downloaded into an Excel spreadsheet or a CSV file that was converted into an Excel spreadsheet.

4.2 Study selection

Two board certified emergency physician study authors independently reviewed each title and abstract from the literature search to select the combined initial list of potential articles. The full text and references of each article or abstract that passed this initial screen of either reviewer were analyzed to further identify missed articles. Full text from each selected article obtained during the initial screen and from references within were read by each reviewer and selected based on pre-determined inclusion/exclusion criteria. At the full-text screening stage, 2 authors independently reviewed each article for final article inclusion and group consensus was used to resolve conflicts. Authors of articles or abstracts that appeared to collect but not publish data within our inclusion criteria were contacted by email on 2 occasions.

The PICO (population, intervention, comparison, outcomes) framework was used to devise our search strategy and inclusion criteria including:

- Patient/population/problem: patients who tested positive for SARS-CoV-2 and simultaneously had testing for other viral pathogens,
- Intervention: performance of viral pathogen or atypical bacterial tests,
- Comparison: none, and
- Outcome: number of viral and atypical bacterial pathogens including Mycoplasma, Chlamydia, Legionella, and Coxiella species.

Exclusion criteria included the following:

- Absence of total number of SARS-CoV-2 patients,
- Absence of simultaneous viral pathogen or atypical bacteria testing,
- Duplicate studies or studies using the same patient database during the same time period,
- Series with <20 patients with SARS-CoV-2, and
- Language other than English.

4.3 Data extraction

Two reviewers independently extracted data from individual articles based on the Meta-analyses of Observational Studies in Epidemiology/MOOSE reporting checklist (Table S3). Extracted data from each article included a description of the study population study details (author, publication year, population country and province/state, design), and specific end point data (patient ages, number of SARS-CoV-2 positive patients, number of viral and atypical pathogen positive patients, specific viral and atypical pathogens tested, specific pathogens found, and type of assay used to test). Group consensus was used to resolve any conflicts regarding data extracted.

4.4 Quality assessment

The quality of evidence across studies and risk of bias for individual studies was independently assessed by 2 study authors. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess quality of evidence across studies as high, moderate, low or very low.18 The risk of bias was assessed for individual studies using the Newcastle-Ottawa Scale for observational studies. With the Newcastle-Ottawa Scale, studies received up to 9 points based on study subjects, study comparability, and outcome of interest assessment. A Newcastle-Ottawa Scale of 0–6 indicates a high risk of bias, and 7–9 indicates a low risk of bias.19-21 For GRADE and Newcastle-Ottawa Scale assessments, any disagreement between the 2 independent reviewers was settled by a third reviewer.

Initial agreement between the 2 initial Newcastle-Ottawa Scale raters overall total points was assessed using Cohen's kappa. A kappa coefficient was considered almost perfect at 0.81–1, showed substantial agreement at 0.61–0.80, moderate agreement at 0.41–0.60, fair agreement at 0.21–0.40, slight agreement at 0.01–0.20, and less than chance at <0.

4.5 Publication bias

Publication bias was evaluated using funnel plot inspection, Begg’s test and Egger’s test with a P < 0.10 considered evidence of bias.22 If publication bias was found, the trim and fill approach was planned to estimate the number of missing studies due to suppression of extreme results to either side of the funnel plot.23

4.6 Data synthesis and statistical analysis

The overall pooled prevalence and 95% confidence intervals (CIs) were estimated using a Freeman-Tukey (arsine square root) transformation, random effects model to calculate a weighted summary. Subset analysis of studies that comprised only adults, serum studies for co-pathogens, reverse transcription polymerase chain reaction (RT-PCR) studies for co-pathogens, large studies (>100 SARS-CoV-2 positive patients), populations outside of Hubei province, published studies, studies graded as having low risk of bias, and populations with 100% co-pathogen investigations was planned. Observed heterogeneity for summary and subgroup analyses were measured using the $I^2$ statistic. $I^2 < 25\%$ was considered low, 30%–60% moderate, 50%–90% substantial, and 75%–100% considerable based on
Initial database searches resulted in 1766 publications of potential relevance with 1000 identified via Google Scholar, 316 publications identified via Medline/PubMed, 324 publications identified via EMBASE, 89 publications identified via Web of Science, 34 publications identified via Wiley’s Cochrane Library, and 3 publications identified via OpenGrey (Figure 1; Supporting Information Table S2) At the full article screening stage, 6 study authors were contacted by mail regarding possible unpublished data from their studies with 1 responding that the data were unavailable. After title/abstract review and full text article screening, 19 articles were included in the final meta-analysis with a total of 1880 patients (27–45) (Figure 2 and Table 1). Eleven included stud-
ies were from peer reviewed journals.\textsuperscript{28,29,31,34–38,40,41,45} Eight studies comprised articles located on a British Medical Journal’s preprint server for health sciences (medRxiv) containing articles that had not yet been peer reviewed.\textsuperscript{27,30,32,33,39,42,43,44}

Laboratory techniques for co-pathogen detection within studies included 8 that used respiratory samples and RT-PCR tests, 5 that used serologic tests (antibodies), 1 that tested both serology and RT-PCR, and 5 that did not specify their testing methods (Table 2). Seventeen studies examined patients for a combination of viruses and atypical bacterial infections although 3 of these 17 studies did not detail pathogens tested. One study only evaluated patients for the presence of influenza A and B and 1 study only evaluated for the presence of Chlamydia or Mycoplasma.

The Newcastle-Ottawa Scale for individual studies ranged from 6–7 with 12 studies (63%) rated as having high quality (Table 3; Supporting Information Figure S1). The interrater agreement for the total Newcastle-Ottawa Scale was substantial for the initial 2 raters ($\kappa = 0.77; 95\% CI = 0.5–1$) Based on GRADE, the overall quality of evidence across all studies was low (Table S4).

Pooling of data found an 11.6% co-infection rate (95% CI = 6.9–17.4) for all patients in all studies, and a 16.8% co-infection rate (95% CI = 8.1–27.9) for the subset of studies/subgroups where 100% of SARS-CoV-2 positive patients were tested for co-pathogens. Pooled prevalence for subgroups is listed (Table 4). A total of 159 viral co-pathogens were found in all studies with influenza found in 55 subjects (35% of viral pathogens). Mycoplasma comprised 86 (74%) of 116 atypical bacteria co-infections. At least 23 patients had >1 co-pathogen although the number of co-infections for each individual was not routinely documented (Table 2).

Heterogeneity was high (substantial) across all studies and all subsets ($I^2$) (Table 4). Univariate meta-regression found no moderators that had a significant effect on heterogeneity (Supporting Information Table S5). Thus, a multivariate meta-regression was not performed. Begg’s correlation test ($z = 1.2, P = 0.23$) and Egger regression (intercept $= 0.7; 95\% CI = −1.4–2.9$) revealed no publication bias (Figure 3).

## 6 LIMITATIONS

The number of cases within this meta-analysis, 1880, was small. Despite this finding, the lower limit of the 95% CI, 6.9%, still implies a meaningful rate of co-infections. It is likely that our study underestimated co-infections because many studies only tested for a subset of respiratory viruses and atypical bacteria.

We excluded studies with <20 patients. Our cutoff of 20 patients is consistent with other meta-analyses requiring populations with at least 20, 25, or 30 patients.\textsuperscript{46–48} We chose to exclude smaller studies, because they have a higher risk of bias and are less likely than large studies to be published if results are negative. The potential for equal weighting of small and large studies in random effects meta-analyses tends to skew results toward smaller studies. Experts also have noted that underpowered/smaller studies often contribute little information.\textsuperscript{59} We compared study size via subgroup analysis and meta-regression and found no effect on heterogeneity or outcome.
| Author, year, published | Region, state, country | Study, design, and date patients admitted | Median, age in years (range unless IQR or SD listed) | Population studied | Total SARS-CoV-2 cases | Total SARS-CoV-2 tested for co-pathogens | Total number cases with viral or atypical pathogens |
|------------------------|------------------------|------------------------------------------|-----------------------------------------------|------------------|----------------------|------------------------------------------|-----------------------------------------------|
| Ai                     | Multiple hospitals Eastern China | Prospective observational 1-22-20 to 2-9-20 | 37 | Consecutive positive CT scans in patients with travel to or contact with individual from Hubei province or individual with COVID-19 | 20 | 20 | 5 |
| Bhatraju               | 9 hospitals, Seattle, WA | Retrospective case series 2-24-20 to 3-9-20 | 64 – mean age (18 SD) | Consecutive admitted patients with COVID-19 | 24 | 23 (influenza tests) | 0 |
| Chen N                 | Jinyintan hospital Wuhan, China | Retrospective case series 1-1-20 to 1-20-20 | 55.5 | Consecutive admitted pneumonia patients with COVID-19 | 99 | 99 | 0 |
| Chen X                 | First Hospital Changsha, Loudi Central hospital, Hunan, China | Retrospective case series 1-23-20 to 2-14-20 | 46 (1–84) | Consecutive admitted patients with COVID-19 with and without pneumonia | 291 | 84 (84 or fewer if no overlap of Mycoplasma/Chlamydia testing) | 51 (only tested 44 for Mycoplasma and 40 for Chlamydia) |
| Ding                   | Tongji hospital Wuhan, China | Retrospective case series Admitted before March 8, 2020 | 49 (39–66) Only influenza cases described | Consecutive admitted patients with COVID-19 | 115 | Not specified | 5 |
| Kim                    | Stanford, CA | Stanford Medical Center, Stanford, CA 3-3-20 to 3-25-20 | Retrospective case series 48.8–mean age (1–98) | Symptomatic patients presenting to an outpatient clinic (n = 50) and emergency department/ED (n = 66) with 16 ED patients being admitted | 116 | 116 | 23 |
| Li J                   | Tongji hospital, Wuhan, China | Retrospective case series 2-8-20 to 2-11-20 | 62 (51–70 IQR) | Consecutive patients with severe COVID-19 pneumonia | 47 | 47 | 5 |
| Li Q                   | Wuhan Union hospital, Wuhan, China | Retrospective case series 2-3-20 to 2-7-20 | 57 (49–69 IQR) | Consecutive patients presenting to a fever clinic who were SARS-CoV-2-positive | 52 | Not specified | 5 |
| Lin                    | 31 | Retrospective case series 1-20-20 to 2-1-20 | No median (80% were aged 18–65) | Consecutive admitted patients who were SARS-CoV-2 positive | 92 | 92 | 6 |

(Continues)
| Author, year, published | Region, state, country | Study, design, and date patients admitted | Median, age in years (range unless IQR or SD listed) | Population studied | Total SARS-CoV-2 cases | Total SARS-CoV-2 tested for co-pathogens | Total number cases with viral or atypical pathogens |
|-------------------------|------------------------|---------------------------------------|-----------------------------------------------|----------------|-----------------------|------------------------------------------|--------------------------------------------------|
| Liu H                  | Xinhuahospital, Shanghai China, Maternal and Child Health hospital of Hubei, Wuhan China | Retrospective case series 1-27-20 to 2-14-20 | Pregnancy SARS-CoV-2-positive: 30 (22–42) Pregnant SARS-CoV-2-negative: 31 Non-pregnant adults: 33.5 (27–58) Children: 3 (0.17–9) | 14 non-pregnant adults, 16 pregnant women, 4 children who were SARS-CoV-2-positive and underwent CT of the chest 26 pregnant females were SARS-CoV-2-negative and diagnosed based on CT and clinically | 60 | Not specified | 2 (Within 60 patient group, Mycoplasma pneumonia (1) found and deleted from analysis Within the 34 SARS-positive cases, 1 viral infection) |
| Liu L                  | Shiyang hospital, Shiyang, China | Retrospective case series 1-23-20 to 2-24-20 | 38 (28–47 IQR) 6 (11.3%) were <14 years | Consecutive SARS-CoV-2 cases admitted to hospital | 53 | 53 | 25 Mycoplasma 6 viral |
| Mo                     | Zhongnan Hospital, Wuhan, China | Retrospective case series 1-1-20 to 2-5-20 | 54 (42–66 IQR) | Consecutive COVID-19 pneumonia admitted patients | 155 | Not specified | 12 |
| Wang M                 | Renmin hospital, Wuhan, China | Retrospective case series 1-20-20 to 2-9-20 | 56 (42–67 IQR) | Consecutive patients tested at Renmin hospital | 104 | 104 | 6 |
| Wang Z                 | Union hospital, Wuhan, China | Retrospective case series 1-16-20 to 1-29-20 | 42 (35–62 IQR) | Consecutive patients admitted to hospital who were positive for SARS-CoV02 | 69 | 28 | 4 |
| Wu J                   | Three hospitals in Jiangsu province | Retrospective case series 1-22-20 to 2-14-20 | 46.1 (30.7–61.5) | Consecutive patients positive for SARS-CoV-2 | 80 | 80 | 0 |
| Wu Q                   | Two hospitals in northern and southern china; Qingdao Women’s and Children’s Hospital; Wuhan Children’s Hospital | Retrospective case series 1-20-20 to 2-27-20 | 6 (0.1–15.1) | Consecutive SARS-CoV-2-positive pediatric cases screened for respiratory pathogens (20 asymptomatic, 24 upper respiratory, 29 mild pneumonia, 1 severe pneumonia) | 74 | 34 | 19 (only 34 tested for upper respiratory pathogens) |
| Xing                   | Renmin hospital, Wuhan, China; 3 Qingdao hospitals, Qingdao, China | Retrospective case series 1-17-20 to 1-16-20 | Qingdao subset: 50 (37–59 IQR) Wuhan subset: 31 (28–38) | Consecutive SARS-CoV-2-positive patients tests at both hospitals | 68 | 68 | 25 |

(Continues)
### TABLE 1 (continued)

| Author, year, published | Region, state, country | Study design, and date patients admitted | Median, age in years (range unless IQR or SD listed) | Population studied | Total SARS-CoV-2 cases | Total SARS-CoV-2 tested for co-pathogens | Total number cases with viral or atypical pathogens |
|-------------------------|------------------------|------------------------------------------|--------------------------------------------------|-------------------|-----------------------|----------------------------------------|-----------------------------------------------|
| Zhang G                 | Zhongnan hospital, Wuhan, China | Retrospective case series 1-2-20 to 2-10-20 | 55 (20–96) | 55 severe cases (admitted to ED or ICU), 166 non-severe admitted cases | 221 | 221 | 33 (email sent 3-30-20 to get breakdown of 17 bacteria can add them in if they are the atypicals) |
| Zhang JJ                | Hospital #7, Wuhan, China | Retrospective case series 1-16-20 to 2-3-20 | 57 (25–87) | Consecutive hospitalized patients diagnosed with viral pneumonia | 140 | 140 | 7 |

*This was the central hospital where all admitted cases were directed in Wuhan.

+Only those with SARS-CoV-2 plus influenza were described in the series.

+Median age unless otherwise specified. Range in parentheses unless otherwise specified. IQR, interquartile range.
| Author | SARS-CoV-2 testing method | Other viruses and atypical bacteria testing method | Type of co-pathogens tested | Total patients with co-pathogens and total organisms found |
|--------|---------------------------|-----------------------------------------------|-----------------------------|----------------------------------------------------------|
| Ai     | RT-PCR via nasopharyngeal swab | RT-PCR via nasopharyngeal swab and Metagenomic sequencing of RNA | Adenovirus, Bordetella pertussis, Chlamydia, Coronavirus (229E, HKU1, NL63, OC43), Influenza A, Influenza A H1, H3, Influenza A H1N1/pdm09, Influenza B, Metapneumovirus, A + B, Mycoplasma, Parainfluenza (1,2,3,4), Rhinovirus/enterovirus, RSV A + B | 5 total patients: 2 Rhino/enterovirus 1 Influenza H3N2 1 Influenza B 1 RSV 4 Haemophilus parainfluenza, 1 Klebsiella, 1 Candida not counted in total as co-respiratory pathogen |
| Bhatrau | RT-PCR via CDC testing guidelines which include either nasopharyngeal, oropharyngeal, nasal mid-turbinate, anterior nares swab; nasal or nasopharyngeal wash/aspirate | RT-PCR via nasopharyngeal swab | University Washington subset: Adenovirus, Bocavirus, Coronavirus (not SARS-CoV-2), Influenza A, Influenza B, Metapneumovirus, Parainfluenza (1,2,3,4), RSV, Rhinovirus Swedish Med. Center: Adenovirus, Bordetella, Chlamydia, Coronavirus (229E, HKU1, NL63, OC43), Influenza A (H1, 2009 H1, H3), Influenza B, Metapneumovirus, Mycoplasma, Parainfluenza (1,2,3,4), Rhinovirus, RSV Virginia Mason Med. Center: Adenovirus, Coronavirus (not SARS-CoV-2), Influenza A, Influenza B, Metapneumovirus, Parainfluenza (no subtype specified), RSV | None |
| Chen N | RT-PCR via throat swab | RT-PCR via throat swab | Adenovirus, Coronavirus (MERS-CoV, SARS-CoV-2) Influenza A (H1N1, H3N2, H7N9), Influenza B, Parainfluenza, RSV | None |
| Chen X | RT-PCR via throat swab | Serum antibody test – (IgM, IgG) | Chlamydia, Mycoplasma | 51 total patients: 22 Chlamydia, 29 Mycoplasma |
| Ding | Not documented | Influenza serology | Influenza A, Influenza B | 3 Influenza A, 2 Influenza B |
| Kim | RT-PCR—site for collection (nasopharyngeal vs throat) not documented | RT-PCR via nasopharyngeal swab | Adenovirus, Chlamydia, Coronavirus (non SARS, non MERS), Influenza A, Influenza B, Rhinovirus/enterovirus, Metapneumovirus, Mycoplasma, Parainfluenza 1,2,3,4, RSV | 23 total patients: 8 Rhinovirus 6 RSV 5 Coronavirus (non SARS, non MERS) 2 Metapneumovirus 1 Parainfluenza 1 1 Parainfluenza 3 1 Parainfluenza 4 1 Influenza A |

(Continues)
| Author | SARS-CoV-2 testing method | Other viruses and atypical bacteria testing method | Type of co-pathogens tested | Total patients with co-pathogens and total organisms found |
|--------|---------------------------|-----------------------------------------------|-----------------------------|----------------------------------------------------------|
| Li J   | RT-PCR via throat swab    | RT-PCR via throat swab (within results influenza antibody tests are described) | Adenovirus, Coronavirus (SARS-CoV-1, MERS), Influenza A (H1N1, H3N2, H7N9), Influenza B, RSV, Parainfluenza, | 5 total patients: 5 Influenza A (within table – results state 5 antibody tests positive) |
| Li Q   | RT-PCR via nasopharyngeal swab | Not specified | Adenovirus, Chlamydia, Coxsackie B, Influenza (no sub-types specified), Mycoplasma, RSV | 5 total patients: 5 With respiratory pathogen not specified |
| Lin    | RT-PCR–site for collection (nasopharyngeal vs throat) not documented | RT-PCR of respiratory tract specimen (naso-vs oropharyngeal source not specified) | Adenovirus, Bocavirus, Coronavirus NL63, Coronavirus 229E, Coronavirus HKU1, Coronavirus OC43, Influenza A, Influenza B, Metapneumovirus, Parainfluenza 1, 2, and 3, Rhinovirus, RSV | 6 total patients: 1 with HKU1+ metapneumovirus, 1 with HKU1+RSV 1 with RSV+parainfluenza 2 1 with RSV+rhinovirus 1 with Metapneumovirus 1 with Rhinovirus |
| Liu H  | RT-PCR via throat swab Subset diagnosed by clinical features plus CT scan of chest | Not specified | Adenovirus, Chlamydia, Coxsackie virus B, Influenza A, Influenza B, Mycoplasma, Parainfluenza (no types specified) RSV | 2 total patients: 1 Mycoplasma 1 RSV |
| Liu L  | RT-PCR–site for collection listed as respiratory tract | Serum antibody test (IgM, IgG) | Adenovirus, Chlamydia, Coxiella, Influenza A, Influenza B, Legionella, Mycoplasma, Parainfluenza (1,2,3), Rhinovirus | 25 Mycoplasma 6 viruses (Influenza A, Influenza B, RSV) |
| Mo     | RT-PCR via throat swab    | Not specified | Adenovirus, Influenza A, Influenza B, Mycoplasma, Parainfluenza, RSV | 12 total patients: 3 Parainfluenza (no type specified) 3 RSV 3 Adenovirus 2 Mycoplasma 2 Influenza A 2 Influenza |
| Wang M | RT-PCR – via nasopharyngeal swab or sputum sample | Respiratory electrophoresis fragment analysis with PCR | Adenovirus, Bocavirus, Chlamydia, Coronavirus, Influenza A (H1N1, H3N2), Influenza B, Metapneumovirus, Mycoplasma, Parainfluenza, Rhinovirus, RSV | 6 total patients: 3 Coronavirus (non-SARS, non-MERS) 2 Influenza A 2 Rhinovirus, 1 Influenza A type H3N2 (it was assumed 2 patients had 2 additional infections in addition to SARS-CoV-2) |

(Continues)
| Author | SARS-CoV-2 testing method | Other viruses and atypical bacteria testing method | Type of co-pathogens tested | Total patients with co-pathogens and total organisms found |
|--------|---------------------------|-------------------------------------------------|-----------------------------|----------------------------------------------------------|
| Wang Z | RT-PCR via throat swab    | Serum Antibody test (IgM, IgG)                  | Not specified               | 2 Chlamydia, 1 RSV, 1 Adenovirus                         |
| Wu J   | RT-PCR via nasal or throat swab | Not specified                          | 9 respiratory pathogens including Influenza A, Influenza B, with the other 7 pathogens not specified | None |
| Wu Q   | RT-PCR via nasopharyngeal swab | Not specified                          | Not specified               | 16 Mycoplasma, 3 RSV, 3 Epstein-Barr, 3 Cytomegalovirus, 1 Influenza (type not specified) |
| Xing   | RT-PCR via throat swab    | Serum antibody test (IgM, IgG)—serum for Qingdao and Wuhan subsets, RT-PCR throat swab for Wuhan subset | Antibody test—Adenovirus, Chlamydia, Coxiella, Influenza A, Influenza B, Legionella, Mycoplasma, Parainfluenza, RT-PCR test (Wuhan)—Adenovirus, Bocavirus, Chlamydia, Coronavirus (SARS-CoV-1), Influenza A, Influenza B, Influenza subtypes (H1N1, H3N2), Mycoplasma, Parainfluenza, RSV, Metapneumovirus, Rhinovirus | 25 total patients: 18 Influenza A, 16 Influenza B, 8 Mycoplasma, 6 Legionella, 1 RSV |
| Zhang G| RT-PCR via pharyngeal swab | RT-PCR via pharyngeal swab, bronchoalveolar lavage, sputum, or bronchial aspirate | Adenovirus, Chlamydia, Influenza A (H1N1, H7N9), Influenza B, Legionella, Mycoplasma, Parainfluenza, RSV | 33 viral co-infections, There were also 17 bacterial co-infections not counted in this number although some may have been Mycoplasma, Chlamydia, or Legionella |
| Zhang J| RT-PCR via pharyngeal swab | Serum antibody test (IgM, IgG)                  | Adenovirus, Chlamydia, Coxsackie B, Cytomegalovirus, Echovirus, Epstein-Barr, Influenza A, Influenza B, Mycoplasma, Parainfluenza (sub types not specified), RSV | 5 Mycoplasma, 1 RSV, 1 Epstein-Barr |

a RT-PCR, reverse transcription, polymerase chain reaction.
### Table 3  
Newcastle Ottawa Scale for risk of bias in cohort or cross-sectional studies

| Items                                                                 | Ai  | Bhatraju | Chen N | Chen X | Ding | Kim | LJ | LQ | Lin | Liu H | Liu L | Mo | Wang M | Wang Z | Wu J | Wu Q | Xing | Zhang G | Zhang JJ |
|------------------------------------------------------------------------|-----|-----------|--------|--------|------|-----|----|----|-----|-------|-------|----|--------|--------|------|------|------|---------|---------|
| Selection                                                              | ✔️  | ✔️        | ✔️     | ✔️     | ✔️   | ✔️  | ✔️ | ✔️ | ✔️  | ✔️    | ✔️    | ✔️ | ✔️     | ✔️     | ✔️   | ✔️   | ✔️   | ✔️      | ✔️      |
| Exposed truly representative of average                               | ✔️  | ✔️        | ✔️     | ✔️     | ✔️   | ✔️  | ✔️ | ✔️ | ✔️  | ✔️    | ✔️    | ✔️ | ✔️     | ✔️     | ✔️   | ✔️   | ✔️   | ✔️      | ✔️      |
| Selection of non-exposed from the same community as exposed            | ✔️  | ✔️        | ✔️     | ✔️     | ✔️   | ✔️  | ✔️ | ✔️ | ✔️  | ✔️    | ✔️    | ✔️ | ✔️     | ✔️     | ✔️   | ✔️   | ✔️   | ✔️      | ✔️      |
| Exposure ascertained by secure record or interview                     | ✔️  | ✔️        | ✔️     | ✔️     | ✔️   | ✔️  | ✔️ | ✔️ | ✔️  | ✔️    | ✔️    | ✔️ | ✔️     | ✔️     | ✔️   | ✔️   | ✔️   | ✔️      | ✔️      |
| Demonstration of outcome of interest (coinfection) not present at start of the study | ✔️  | ✔️        | ✔️     | ✔️     | ✔️   | ✔️  | ✔️ | ✔️ | ✔️  | ✔️    | ✔️    | ✔️ | ✔️     | ✔️     | ✔️   | ✔️   | ✔️   | ✔️      | ✔️      |
| Comparability of those with versus without co-infection               |     |           |        |        |      |     |    |    |     |       |       |    |        |        |      |      |      |         |         |
| Comparable groups based on major factor (age)                         | xx  | xx        | xx     | xx     | xx   | xx  | xx | xx | xx  | xx    | xx    | xx | xx     | xx     | xx   | xx   | xx   | xx       | xx       |
| Comparable groups based on minor factor (Gender)                      | xx  | xx        | xx     | xx     | xx   | xx  | xx | xx | xx  | xx    | xx    | xx | xx     | xx     | xx   | xx   | xx   | xx       | xx       |
| Outcome (0 or 1 point each)                                            | ✔️  | ✔️        | ✔️     | ✔️     | ✔️   | ✔️  | ✔️ | ✔️ | ✔️  | ✔️    | ✔️    | ✔️ | ✔️     | ✔️     | ✔️   | ✔️   | ✔️   | ✔️      | ✔️      |
| Adequate assessment of outcome                                         | ✔️  | ✔️        | ✔️     | ✔️     | ✔️   | ✔️  | ✔️ | ✔️ | ✔️  | ✔️    | ✔️    | ✔️ | ✔️     | ✔️     | ✔️   | ✔️   | ✔️   | ✔️      | ✔️      |
| Follow-up long enough for outcome to occur                             | ✔️  | ✔️        | ✔️     | ✔️     | ✔️   | ✔️  | ✔️ | ✔️ | ✔️  | ✔️    | ✔️    | ✔️ | ✔️     | ✔️     | ✔️   | ✔️   | ✔️   | ✔️      | ✔️      |
| Adequacy of follow-up: subjects lost to follow-up unlikely to introduce bias | ✔️  | xx        | xx     | xx     | xx   | xx  | xx | xx | xx  | xx    | xx    | xx | xx     | xx     | xx   | xx   | xx   | xx       | xx       |
| Total score                                                            | 7   | 6         | 7      | 6      | 7    | 6   | 7  | 7  | 6   | 7     | 7     | 7  | 6      | 6      | 7    | 7    | 7     | 7        | 7        |

✔️, present  ❌, absent.

*In general, consecutive admissions or consecutively screened patients were felt to be representative of average patient with SARS-CoV-2 in that clinic or hospital.*

*Newcastle-Ottawa Scale instructions state that the disease and not mortality should be the major outcome of interest. For COVID-19, if infections were new, this criterion was met.*
TABLE 4  Pooled prevalence for all studies and subsets

| Study subsets                                      | Studies(n) | Subjects(n) | Pooled prevalence (95% CI) | Heterogeneity I² statistic (95% CI) |
|---------------------------------------------------|------------|-------------|-----------------------------|-------------------------------------|
| All Studies                                        | 19         | 1880        | 11.6 (6.9–17.4)             | 0.92 (0.89–0.94)                    |
| Adults only                                        | 15         | 1577        | 8.9 (4.9–13.9)              | 0.9 (0.85–0.93)                     |
| Viral co-pathogens                                 | 16         | 1469        | 7 (3.8–11.1)                | 0.86 (0.80–0.91)                    |
| 100% of subjects tested for co-pathogens          | 15         | 1210        | 16.8 (8.1–27.9)             | 0.95 (0.94–0.97)                    |
| Atypical bacterial co-pathogens                   | 11         | 1150        | 7.9 (2.3–16.5)              | 0.95 (0.93–0.97)                    |
| Low risk of bias studies                           | 12         | 1110        | 12.3 (5.5–21.3)             | 0.94 (0.91–0.96)                    |
| Published studies                                  | 11         | 1107        | 7.2 (2.8–13.5)              | 0.92 (0.88–0.95)                    |
| RT-PCR testing                                     | 9          | 761         | 9.1 (3.8–16.4)              | 0.88 (0.80–0.93)                    |
| Large (>100 patients with SARS-CoV-2)             | 7          | 1142        | 10.5 (6.3–15.5)             | 0.84 (0.70–0.92)                    |
| Outside Hubei province                             | 6          | 561         | 21 (6–41.9)                 | 0.96 (0.93–0.97)                    |
| Serum antibody testing                             | 6          | 488         | 26.8 (7.9–51.9)             | 0.97 (0.95–0.98)                    |

CI, confidence interval.

* Pooled prevalence for viral or atypical co-pathogen co-infection.

** Five studies did not specify type of testing and were not included in subset.

FIGURE 3  Funnel plot of included studies—viral and atypical bacteria co-infections

|  |
|---|
| **DISCUSSION** |

We found a pooled prevalence of 11.6% for viral and atypical pathogens in 1880 patients who were SARS-CoV-2-positive when all subjects within studies were included and 16.8% when patients with 100% co-pathogen testing were analyzed. Viral co-pathogens comprised 159 and atypical bacteria comprised 116 infections. Subset analysis of studies comprised of adults only found a pooled prevalence of 8.9% co-infections. Subset analysis of viral and atypical bacterial co-pathogens found a pooled prevalence of 7% and 7.9%, respectively. These results indicate that co-infections with both respiratory viruses and atypical bacteria are a common and potentially important factor in patients with COVID-19.

The majority of individuals within included studies were symptomatic and were admitted to the hospital. It is possible that co-infection rates are higher in these patients and co-infection contributed to symptoms, disease severity, and hospitalization. Testing of relatively asymptomatic SARS-CoV-2 positive patients for other pathogens will be required to determine if a similar rate of co-infections exists in a less ill population of SARS-CoV-2-positive outpatients.

All studies contained patients enrolled from January to March 2020. It is likely that the presence and timing of viral respiratory outbreaks (especially influenza) influenced the prevalence of co-pathogens. Although influenza virus infections are detected year-round, peak activity in the northern hemisphere is typically December through March. This time frame coincides with the current SARS-
CoV-2 outbreak. Because of this phenomenon, co-infection rates during other “non-flu” months within the southern hemisphere, and during local co-pathogen outbreaks, are likely to differ.

Only 6 studies evaluated serum antibody tests with this method detecting co-infections in a 26.8% of COVID-19 patients. It is possible that application of this testing method across all studies would reveal an even higher overall co-infection rate than found in our study. Alternately, it is possible that positive serology indicated recent and not acute infection in included patients. Positive RT-PCR tests also might indicate recently resolved infection or colonization. Byington et al62 found that 16% of children with respiratory viruses had positive PCR tests for 3 or more weeks after an initial infection. Tests for bocavirus and rhinoviruses stayed positive for a longer period than other respiratory viruses although symptomatic viral infections lasting over 3 weeks occurred with most tested viruses (adenovirus, coronavirus [all subtypes 229E, HKU1, NL63, OC43], influenza, human metapneumovirus, parainfluenza, and respiratory syncytial virus).62 It is uncertain if prolonged viral test positivity without infection also applies to adults.

Although RT-PCR was used to detect viruses in 17 included studies, these tests have not shown a consistent level of accuracy in detecting viral pathogens. Basile et al63 reviewed point-of-care diagnostic tests including RT-PCR for respiratory infections and found that sensitivity for viral pathogens varied from 20%–94% depending on the type of test, the individual viruses analyzed, the manufacturer, and the specific technique used. Zhang et al64 combined serology (antibody testing) with RT-PCR to analyze the additive diagnostic yield with a combined testing approach. In their study, antibody testing increased detection of viral pathogens between 12%–49% depending upon the virus studied.64 Only a subset of 1 study in our meta-analysis combined serology and RT-PCR in their population.63

Separate from issues with testing, co-infection with other respiratory pathogens has important implications for diagnosis and prognosis. It is possible that the clinical presentation, laboratory results, radiological findings, and outcome differ between SARS-CoV-2 positive patients with and without co-infections. Burk et al65 found that coexisting viral and bacterial pathogens increased mortality in community-acquired pneumonia. Other studies conflict on whether or not co-infection with Chlamydia pneumonia in individuals with SARS-CoV-1 is associated with increased disease severity and mortality.66 Prospective studies detailing presenting historic, physical examination, and laboratory/radiological features will be needed to determine how patients with respiratory pathogens differ from those without co-pathogens.

Medical management might differ for COVID-19 patients with and without co-infections. Although there are no currently approved treatments for COVID-19, anti-virals for influenza and antibiotics for atypical bacteria would likely benefit individuals with those co-infections. When treatments are developed for COVID-19, clinicians will need to understand the interactions of medicines and side effects of combining medicines when treating individuals with COVID-19 and co-pathogens.

In summary, we found an 11.6% pooled prevalence for co-infection with viruses and atypical bacteria in studies of SARS-CoV-2-positive patients. Pooled prevalence was even higher, 16.8%, in studies that tested 100% of patients for co-pathogens. These results indicate that clinicians should not rely on positive tests for these co-infections when considering whether or not to test patients for SARS-CoV-2. Further study is needed to determine if co-infections alter clinical features, laboratory and radiological examinations, and outcomes for patients with COVID-19.

**CONFLICTS OF INTEREST**
The authors declare no conflicts of interest.

**ORCID**
Steven G. Rothrock MD https://orcid.org/0000-0003-3528-662X

**REFERENCES**
1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-733.
2. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19–11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19–11-march-2020. Accessed April 12, 2020.
3. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 104. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200503-covid-19-sitrep-104.pdf?sfvrsn=53328f46_4
4. Centers for Disease Control and Prevention. Updated guidance on evaluating and testing persons for coronavirus disease 2019 (COVID-19). https://emergency.cdc.gov/han/2020/HAN00429.asp. Published March 8, 2020. Accessed April 12, 2020.
5. Bordi L, Nicastri E, Scorzolini L, et al. Differential diagnosis of illness in patients under investigation for the novel coronavirus (SARS-CoV-2), Italy, February 2020. Euro Surveill. 2020;25(8):2000170.
6. Alaska public health update. Updated criteria for coronavirus disease 2019 (COVID-19) persons under investigation (PUI) reporting and testing in Alaska. http://dhss.alaska.gov/Epi/Documents/phan/AKPHAN_20200304_COVID-19.pdf Accessed April 12, 2020.
7. Kansas Department of Health and Environment. Definitions of a person under investigation. Updated March 17, 2020. http://www.kdheks.gov/coronavirus/toolkit/COVID_2019_Flowchart_for_healthcare_facilities.pdf. Accessed April 12, 2020.
8. Michigan interim 2019 coronavirus (COVID-19) person under investigation (PUI)/case report form cover sheet. https://www.michigan.gov/documents/mdhhs/MDHHS_CDC_PUI_Form_and_Cover_Sheet_Fillable_v02.03.2020_680230_7.pdf Accessed April 12, 2020.
9. South Dakota department of health. COVID updates and information. https://doh.sd.gov/news/coronavirus.aspx. Accessed April 12, 2020.
10. Pan American Health Organization. WHO. Epidemiological update novel coronavirus (2019-nCoV). 20 January 2020. https://www.paho.org/hq/index.php?option=com_content&view=article&id=15676:20-january-2020-novel-coronavirus-ncov-epidemiological-update&catid=2103&Itemid=42346&lang=en Last accessed April 12, 2020.
11. World Health Organization. Laboratory testing of human suspected cases of novel coronavirus (nCoV) infection. Interim guidance. January 10, 2020. https://apps.who.int/iris/bitstream/handle/10665/330374/WHO-2019-nCoV-laboratory-2020.1-eng.pdf?sequence=1&isAllowed=y Last accessed April 12, 2020.
12. Touzard-Romo F, Tape C, Lonks JR. Co-infection with SARS-CoV-2 and human metapneumovirus. RI Med J 2020;103:75-76.
13. Wu X, Cai Y, Huang X, et al. Co-infection with SARS-CoV-2 and influenza in patient with pneumonia, China. Emerg Infect Dis 2020;26(6). doi: 10.3201/eid2606.200299. [Epub ahead of print]
14. McIntosh K, Hirsch MS, Bloom A. Coronavirus disease 2019 (COVID-19). UpToDate. https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19?source=history_widget Updated March 27, 2020. Accessed March 29, 2020.

15. Asner SA, Science ME, Tran D, Smieja M, Merglen A, Mertz D. Clinical disease severity of respiratory viral co-infection versus single viral infection: a systematic review and meta-analysis. PLoS One. 2014;9(6):e93932.

16. Klein EY, Monteforte B, Gupta A, et al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses 2016;10:394-403.

17. Wang M, Cal F, Wu X, Wu T, Su X, Shi Y. Incidence of viral infection moniapatients co-infected with 2019 novel coronavirus and influenza virus I Wuhan, China. J Med Virol 2020 Mar 20. doi: 10.1002/jmv.25781. [Epub ahead of print]

18. McIntosh K, Hirsch MS, Bloom A. Coronavirus disease 2019 (COVID-19). UpToDate. https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19?source=history_widget Updated March 27, 2020. Accessed March 29, 2020.

19. Lee SS, Seo IW, Cho MS, Shin YS. Comparison of femoral tunnel length and obliquity of anatomic versus nonanatomic ante- rior cruciate ligament reconstruction: a meta-analysis. PLoS One 2020;15(3):e0230497.

20. Nha KW, Shin YS, Kwon HM, Sim JA, Na YG. Navigated versus conventional technique in high tibial osteotomy: a meta-analysis focusing on weight bearing effect. Knee Surg Relat Res 2019;31:81-102.

21. Takah NF, Atem JA, Amidine LN, Malisheini M, Murwenehmen. Male partner involvement in increasing the uptake of infant antiretroviral prophylaxis/treatment in sub Saharan Africa: a systematic review and meta-analysis. BMC Public Health 2018;18(1):249.

22. Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomized controlled trials. BMJ 2011;343:d4000.

23. Terrin N, Schmid CH, Lau J, Olkin I. Adjusting for publication bias in the presence of heterogeneity. Stat Med 2003;22:2113-2126.

24. Deeks JJ, Higgins JPT, Altman G, Cochrane Statistical Methods Group. Chapter 9.5 Heterogeneity. In Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at www.handbook.cochrane.org.

25. Schüenemann H, Brozek J, Guyatt G, Oxman A (editors). The GRADE Working Group. Chapter 5.2.2 Inconsistency of Results. In GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html Updated October 2013.

26. Suurmond R, van Rhee H, Hak T. Introduction, comparison, and validation of Meta-Essentials: a free and simple tool for meta-analysis. Res Synth Methods 2017;8(4):537-553.

27. Ai JW, Zhang HC, Xu T. Optimizing diagnostic strategy for novel coronavirus pneumonia, a multi-center study in Eastern China. medRxiv https://www.medrxiv.org/content/10.1101/2020.02.13.20022673v1 https://doi.org/10.1101/2020.02.13.20022673

28. Bhatraju PK, Ghassemiem BH, Nichols M, et al. COVID-19 in critically ill patients in the Seattle Region—case series. N Engl J Med 2020; Mar 30. doi: 10.1056/NEJMoa2004500. [Epub ahead of print]

29. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-513.

30. Chen X, Zheng F, Qian Y, et al. Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China: a double center observational study. medRxiv https://doi.org/10.1101/2020.03.03.20030353

31. Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of pneumonia patients co-infected with 2019 novel coronavirus and influenza virus I Wuhan, China. J Med Virol 2020 Mar 20. doi: 10.1002/jmv.25781. [Epub ahead of print]

32. Li J, Zhang Y, Wang F, et al. Sex differences in clinical findings among patients with coronavirus disease 2019 (COVID-19) and severe condition. medRxiv https://doi.org/10.1101/2020.02.27.20027524

33. Li Q, Ding X, Xia G, et al. A simple laboratory parameter facilitates early identification of COVID-19 patients. medRxiv https://doi.org/10.1101/2020.02.13.20022380

34. Lin D, Liu L, Zhang M, et al. Co-infections of SARS-CoV-2 with multiple common respiratory pathogens in infected patients. Sci China Life Sci 2020; https://doi.org/10.1007/s11427-020-1668-5

35. Liu H, Liu F, Li J, et al. Clinical and CT imaging features of the COVID-19 pneumonia: focus on pregnancy women and children. J Infect 2020 Mar 20; pii: S0163-4452(20)30118-3. doi: 10.1016/j.jinf.2020.03.007. [v]

36. Liu L, Lei X, Xiao X, et al. Epidemiological and clinical characteristics of COVID-19 patients in Shiyian city of Hubei province, China. Lancet Infect Dis 2020 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3556661&download=yes&redirectFrom=true [SSRN-id3556661.pdf] Accessed April 12, 2020

37. Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis 2020; https://doi.org/10.1093/cid/ciaa270

38. Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA 2020; Apr 22. doi: 10.1001/jama.2020.6775. [Epub ahead of print Apr 15]

39. Wang M, Wu Q, Xu W, et al. Clinical diagnosis of 274 samples with 2019 novel coronavirus in Wuhan. medRxiv https://doi.org/10.1101/2020.02.12.20023277 Accessed April 12, 2020.

40. Wang Z, Yang B, Li Q, et al. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis 2020; 2020 Mar 16. pii: cia272. doi: 10.1093/cia/cia272. [Epub ahead of print]

41. Wu J, Liu J, Zhao X, et al. Clinical characteristics of imported cases of COVID-19 in Jiangsu Province: a multicenter descriptive study. Clin Infect Dis 2020 Feb 29. pii: cia199. doi: 10.1093/cid/cia199. [Epub ahead of print]

42. Wu Q, Xing Y, Shi L, et al. Epidemiological and clinical characteristics of children with coronavirus disease 2019. medRxiv https://doi.org/10.1101/2020.03.19.20027078 Accessed April 12, 2020.

43. Xing Q, Li G, Xing Y, et al. Precautions are needed for COVID-19 patients with coinfection of common respiratory pathogens. JAMA 2020; 2020 Feb 29. pii: ciaa199. doi: 10.1093/cjima/ciaa199. [Epub ahead of print]

44. Zhang G, Hu C, Luo L, et al. Clinical features and outcome of 1221 patients with COVID-19 in Wuhan, China. medRxiv https://doi.org/10.1101/2020.03.02.20030452 Accessed April 12, 2020.

45. Zhang JJ, Dong X, Cao Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; doi: 10.1111/all.14238.

46. Familiar F, Cinque ME, Chahla J, et al. Clinical outcomes and failure rates of osteochondral allograft transplantation in the knee: a systematic review. Am J Sport Med 2018;46:3541-3549.

47. Wiffen PJ, Derry S, Moore RA, et al. Oral paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev 2017;7:CD012637.

48. Kaminski A, Kamper A, Thaler K, Chapman A, Gartlehner G. Antide pressants for the treatment of abdominal pain-related functional gastrointestinal disorders in children and adolescents. Cochrane Database Syst Rev 2011;2011(7):CD008013.

49. Turner RM, Bird SM, Higgins JPT. The impact of study size on meta analyses: examination of underpowered studies in Cochrane reviews. PLoS One 2013;8(3):e59202.

50. Cook DJ, Guyatt GH, Ryan G, et al. Should unpublished data be included in meta-analyses? Current convictions and controversies. JAMA 1993;269:2749-2753.

51. Boutron I, Page MJ, Higgins JPT, Altman DG, Lundh A, Hrobjartsson A. Selective publication of study reports.7.2.3.1 In Higgins JPT, Green
S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available at: www.training.cochrane.org/handbook.

52. Lefebvre C, Glanville J, Briscoe S, et al. Ongoing studies and unpublished data sources. 4.3.2. In Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.

53. Schmuker CM, Blumle A, Schell LK, et al. Systematic review finds that study data not published in full text articles have unclear impact on meta-analyses results in medical research. PLoS One. 2017;12(4):e0176210.

54. Higgins JPT. Commentary in meta-analyses should be expected and appropriately quantified. Int J Epidemiol 2008;37:1158-1160.

55. Fleming PS, Koletsi D, Ioannidis FPA, Pandis N. High quality of the evidence for medical and other health-related interventions was uncommon in Cochrane Systematic Reviews. J Clin Epidemiol 2016;78:34-42.

56. Nielsen SM, Zobbe K, Kristensen LE, Christensen R. Nutritional recommendations for gout: an update from clinical epidemiology. Autoimmun Rev 2018;17:1090-1096.

57. Alexander PE, Bero L, Montori VM, et al. World Health Organization recommendations are often based on low confidence in effect estimates. J Clin Epidemiol 2014;67:629-634.

58. Alexander PE, Brito JP, Neumann I, et al. World Health Organization strong recommendations based on low-quality evidence (study quality) are frequent and inconsistent with GRADE guidance. J Clin Epidemiol 2016;72:98-106.

59. Alexander PE, Gionfriddo MR, Li SA, et al. A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance. J Clin Epidemiol 2016;70:111-122.

60. Balsch H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. rating the quality of evidence. J Clin Epidemiol 2011;64:401-406.

61. Centers for Disease Control and Prevention. Influenza (Flu). When is flu season? https://www.cdc.gov/flu/about/season/flu-season.htm Accessed April 10, 2012.

62. Byington CL, Ampofo Krow, Stockmann C, et al. Community surveillance of respiratory viruses among families in the Utah Better Identification of Germs-Longitudinal Viral Epidemiology (BIG-LoVE) study. Clin Infect Dis 2015;61:1217-1224.

63. Basile K, Kok J, Dwyer DE. Point-of-care diagnostics for respiratory viral infections. Expert Rev Mol Diag 2018;18:75-83.

64. Zhang Y, Sakthivel SK, Bramley A, et al. Serology enhances molecular diagnosis of respiratory virus infections other than influenza in children and adults hospitalized with community-acquired pneumonia. J Clin Microbiol 2016;28:79-89.

65. Burk M, El-Kersh K, Saad M. Viral infection in community-acquired pneumonia: a systematic review and meta-analysis. Eur Respir Rev 2016;25:178-188.

66. Zahariadis G, Gooley TA, Ryall P, et al. Risk of ruling out severe acute respiratory syndrome by ruling in another diagnosis: variable incidence of atypical bacterial co-infection based on diagnostic assays. Can Respir J 2006;13:17-22.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Davis B, Rothrock AN, Swetland S, Andris H, Davis P, Rothrock SG. Viral and atypical respiratory co-infections in COVID-19: a systematic review and meta-analysis. JACEP Open. 2020;1:533–548. https://doi.org/10.1002/emp2.12128